Equivalence Study of Dorzolamide 2% Eye Drops Solution

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00878917
Recruitment Status : Completed
First Posted : April 9, 2009
Last Update Posted : February 12, 2010
Information provided by:
Alfred E. Tiefenbacher (GmbH & Co. KG)

April 8, 2009
April 9, 2009
February 12, 2010
April 2009
February 2010   (Final data collection date for primary outcome measure)
intraocular pressure (IOP)-lowering [ Time Frame: 9 weeks ]
Same as current
Complete list of historical versions of study NCT00878917 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Equivalence Study of Dorzolamide 2% Eye Drops Solution
Randomized, Double-Masked, Active Controlled, Crossover Phase III Equivalence Study of Dorzolamide 2% Eye Drops Solution In Subjects With Open Angle Glaucoma Or Ocular Hypertension
The study aims to prospectively prove the equivalence of the test product and the reference solution in lowering intraocular pressure in patients with open angle glaucoma and ocular hypertension. For this purpose the patients are randomized into two sequences of study drug administration in a crossover study with an adequate wash-out period.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
  • Open Angle Glaucoma
  • Ocular Hypertension
Drug: Dorzolamide 2 % eye drops solution
1 drop into eye(s) three times a day for the duration of each treatment phase
Experimental: Dorzolamide
Intervention: Drug: Dorzolamide 2 % eye drops solution

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
February 2010
February 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patients of any race aged 18 years or older
  • A clinical diagnosis of open angle glaucoma, pseudoexfoliation or pigment dispersion glaucoma, or ocular hypertension in one or both eyes
  • IOP controllable on one drug treatment in the study eye in way that assures clinical stability of vision and the optic nerve throughout the study
  • Baseline IOP between 18 and 32 mmHg in the study eye (in eyes not included in the study IOP must have been controllable on no pharmacologic treatment or on the study medicine only)
  • Best corrected visual acuity of 20/200 or better in the study eye(s)
  • Ability of subject to understand character and individual consequences of clinical trial
  • Signed and dated informed consent of the subject must be available before start of any specific trial procedures
  • Women with childbearing potential have to practicing a medically accepted contraception during trial and a negative pregnancy test (serum or urine) should be existent before trial. Reliable contraception are systemic contraceptives (oral, implant, injection) and diaphragm or condoms with spermicidal. Women that are sterile by surgery or for more than two years postmenopausal can be participate in the trial.

Exclusion Criteria:

  • Chronic or recurrent inflammatory eye disease
  • Ocular trauma within the past six months
  • Current ocular infection, i.e. conjunctivitis or keratitis
  • Any abnormality preventing reliable applanation tonometry
  • Intraocular surgery or laser treatment within the past three months
  • Inability to discontinue contact lens wear during the study
  • Use of any systemic medication that would affect IOP with less than a

    1-month stable dosing regimen before the screening visit

  • Pregnancy and lactation
  • History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
  • Participation in other clinical trials during the present clinical trial or within the last four weeks
  • Medical or psychological condition that would not permit completion of the trial or signing of informed consent
  • Subject is allergic to sulfonamides
  • Severe renal dysfunction or hyperchloraemic acidosis
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr. Harm Peters, Alfred E. Tiefenbacher (GmbH & Co. KG)
Alfred E. Tiefenbacher (GmbH & Co. KG)
Not Provided
Principal Investigator: Norbert Pfeiffer, Prof. Dr. Department of Opthalmology, Johannes Gutenberg University Mainz
Alfred E. Tiefenbacher (GmbH & Co. KG)
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP